2113 - Olanzapine

Material & Volume
  • Serum, 1ml
Clinical Information

Olanzapine is a medication agent of the group of atypical neuroleptics and is structurally related close to the effective ingredient clozapine. It has antimanic effects (against megalomania and hallucinations) and works mood stabilising (against loss of interest, for example and lethargy) and is administered for schizophrenia, bipolar disorders and mania. The precise therapeutic effect mechanism is not fully clarified, but is presumed to effect antagonism at the cerebral serotonin- and dopamine -receptors. Moreover, olanzapine has affinity to other receptors (the muscarinic-, histaminic- and adrenerg alpha receptors). Frequent side effects are somnolence and body-weight increase as well as a worsening of Parkinson symptoms in Parkinson patients.

Type of drug: Antipsychotic
Metabolism: UGT1A4, UGT2B10, FMO, CYP1A2, CYP2D6, P-gp(ABCB1)
Half life t½: 30-60h
Steady State: 1-2 weeks
TDM: highly recommended/ norm of treatment
Additional informations: Under olanzapine pamoate, patients have a high risk of post-injection syndrome if the concentration exceeds 100ug/l. Half-life for the pamoate 30 days.

More information
Related analyses
Description Material
Olanzapine Serum
Desmethylolanzapin Serum
Product names
Analyses groups
  • Zyprexa®
Position / Price
Position: Mandatory provision
Price: CHF 140.00
+ Processing fee:
(per order and per day)
CHF 24.00
Executing laboratory
labor team w ag
Blumeneggstrasse 55
9403 Goldach
Execution time
1 day
During opening-hours:
Outside opening-hours: